Indeed, there is preclinical evidence for the immunogenicity of a number of neo-epitopes arising from hallmark glioma mutations, including EGFRvIII (an intragenic deletion of exons 2–7 of the epidermal growth factor receptor), IDH1R132H and H3.3K27M 35–37. Here, EGFR is linked to central nervous system cancer.